Facebook      Twitter




Release Date: February 2, 2009
Expiration: Expired (February
28, 2010)
Content is provided for informational purposes only.

This is the recorded version of a live webinar that took place on December 17, 2008. It is designed to provide physicians, nurses, and other healthcare professionals involved in day-to-day treatment decisions for developmentally disabled adults and children with up-to-date information regarding the evaluation and management of osteoporosis encountered in this special needs population.


Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), UMDNJ-Center for Continuing & Outreach Education.

Target Audience

Primary care and specialty physicians, nurses and other healthcare professionals who are responsible for the evaluation and management of children and adults with mental retardation, cerebral palsy, epilepsy, autism and other developmental disabilities; e.g. staff at State Developmental Centers in New Jersey and throughout the country; members of the American Academy of Developmental Medicine and Dentistry, members of the Developmental Disabilities Nurses Association, and the National Association of State Directors of Developmental Disabilities Services.

Learning Objectives

  • Discuss the underlying basic pathophysiological mechanisms that lead to osteoporosis in persons with developmental disabilities.
  • Describe how osteoporosis is diagnosed in persons with developmental disabilities.
  • Discuss various treatment/management strategies that may be effective when osteoporosis is encountered in persons with developmental disabilities.


Seth M. Keller, MD
Pathophysiology of Osteoporosis
Sunil Wimalawansa, MD, PhD, MBA, FRCP, DSc
Diagnosis and Evaluation of Osteoporosis
Steven M. Petak MD, FACE, JD
Prevention andTreatment of Osteoporosis
Joan M. Lappe, PhD, RN, FAAN
Panel/Q & A
All Presenters

Method of Instruction

Participants should read the learning objectives and review the presentations in their entirety. After reviewing the presentations, complete the post- test consisting of a series of multiple-choice and True/ False questions and submit the course evaluation. A credit letter will be emailed to the address that you provide. Estimated time to complete this activity as designed is 1.5 hours.



UMDNJ-Center for Continuing and Outreach Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UMDNJ-Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACNP and AAPA accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.


DDNA is an approved provider of continuing education by the New York State Nurses Association, which is accredited as an approver of continuing education by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 7AURLS-PRV-08.

This offering is approved for 1.5 hours of continuing education (CE) for nurses.



Philip May, MD
Clinical Associate Professor, Department of Medicine
UMDNJ Robert Wood Johnson Medical School
New Brunswick, NJ


Sunil Wimalawansa, MD, PhD, MBA, FRCP, DSc
Professor of Medicine
Chief, Endocrinology, Metabolism, and Nutrition
Director, Regional Osteoporosis Center
UMDNJ Robert Wood Johnson Medical School
New Brunswick, NJ

Steven M. Petak, MD, FACE, JD
Director, Osteoporosis Center and Bone Densitometry Unit
Clinical Assistant Professor
University of Texas Medical School
Houston, Texas
President, International Society of Clinical Densitometry (ISCD)

Joan M. Lappe, PhD, RN, FAAN
Professor of Nursing and Professor of Medicine
Osteoporosis Research Center
Creighton University Medical Center
Omaha, Nebraska

Seth M. Keller, MD
Neurology Consultants of Burlington County
American Academy of Developmental Medicine and Dentistry
Hunterdon, New Lisbon, Vineland Developmental Centers
Lumberton, NJ


In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants:

  1. the existence of any financial interest or other relationships with proprietary entities producing health care goods or services, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and
  2. the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device that is not yet approved.

Faculty Disclosure Declarations

The following faculty have no significant financial relationships to disclose and do not intend to discuss an unapproved or investigated use of a product/device:

Seth M. Keller, MD
Philip May, MD

Planning committee members, Patrick Dwyer, Attasha Nurse,Robin Preisler and Liz Ward from UMDNJ and Mary Alice Willis, RN, MSN from DDNA have no relevant financial relationships.

The following faculty have significant financial relationships to disclose and do not intend to discuss an unapproved or investigated use of a product/device:

Joan M. Lappe, PhD, RN, FAAN
Speakers Bureau: Roche/GlaxoSmithKline Pharmaceuticals
Member, Scientific Advisory Board: Bayer HealthCare Consumer Care, DiaSorin Inc. 

Steven Petak, MD, FACE, JD
Speakers Bureau: Roche/GlaxoSmithKline, Eli Lilly, Novartis, Aventis/P&G

Sunil J. Wimalawansa, MD, PhD, MBA
Speakers Bureau: Novartis (rarely participated)

Off-Label Usage Disclosure

This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.


The views expressed in this activity are those of the faculty and it should not be inferred or assumed that they are expressing the views of UMDNJ. The recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate, however, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.

Copyright © 2009 UMDNJ-Center for Continuing and Outreach Education. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing and Outreach Education.

Grantor Acknowledgement

We gratefully acknowledge the following companies for providing educational grants for this program: Merck and Company, Inc., and Eli Lilly and Company.

System Requirements

This program is best viewed at a resolution of 1024 x 768 or higher using Microsoft Internet Explorer 6 or later. A high-speed Internet connection, such as ISDN, T-1, DSL or Cable, is recommended.

You must have the Adobe Flash Player installed on your computer in order to view this program. If you do not have the Adobe Flash Player, you can download this free plug-in from Adobe.com.

Please note that due to a technical difficulty, the second slide in each presentation does not advance; however, the audio continues without interruption and overall content has not been affected.

We encourage you to download the case history that will be addressed in this presentation.


© Copyright 2017, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy